GlassScriptPhysician profile
Alex Rokni
NPI 1265067151
$2,338.46
in general payments reported to CMS, 2019-2025
16 companies · $1,063 in 2025
The $1,063 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $401 · 2024: $875 · 2025: $1,063.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,837 · Education: $502.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,836.53 |
| Education | $501.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $696.67 | 2023-2025 | Tremfya |
| Abbvie INC. | $403.56 | 2023-2025 | Rinvoq, Skyrizi |
| Janssen Scientific Affairs, LLC | $272.15 | 2024-2025 | Tremfya |
| Genzyme Corporation | $235.13 | 2023-2025 | |
| Lilly USA, LLC | $178.90 | 2023-2025 | Ebglyss, Taltz, Olumiant |
| Sanofi-Aventis U.S. LLC | $170.00 | 2025 | |
| Sun Pharmaceutical Industries INC. | $72.00 | 2024 | |
| Incyte Corporation | $58.04 | 2024 | Opzelura |
| Ucb, INC. | $38.68 | 2025 | Bimzelx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.67 | 2024 | Spevigo |
| Pfizer INC. | $34.32 | 2024-2025 | |
| Galderma Laboratories, L.P. | $32.14 | 2025 | Nemluvio |
| Therakos LLC | $29.84 | 2025 | Cellex, Uvadex |
| Novartis Pharmaceuticals Corporation | $29.30 | 2024 | |
| Amgen INC. | $26.23 | 2025 | Otezla |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $25.83 | 2023 | Siliq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alex Rokni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.